Lee Gun Tak, Jeong Daun, Park Jong Eun, Lee Se Uk, Kim Taerim, Yoon Hee, Cha Won Chul, Sim Min Seob, Jo Ik Joon, Hwang Sung Yeon, Shin Tae Gun
Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Department of Emergency Medicine, College of Medicine, Kangwon National University, Chuncheon, Gangwon-do, Republic of Korea.
Heliyon. 2024 Aug 15;10(16):e36345. doi: 10.1016/j.heliyon.2024.e36345. eCollection 2024 Aug 30.
We assessed the efficacy of anti-hyperkalemic agents for alleviating hyperkalemia and improving clinical outcomes in patients with out-of-hospital cardiac arrest (OHCA).
This was a single-center, retrospective observational study of OHCA patients treated at tertiary hospitals between 2010 and 2020. Adult patients aged 18 or older who were in cardiac arrest at the time of arrival and had records of potassium levels measured during cardiac arrest were included. A linear regression model was used to evaluate the relationship between changes in potassium levels and use of anti-hyperkalemic medications. Cox proportional hazards regression analysis was performed to analyze the relationship between the use of anti-hyperkalemic agents and the achievement of return of spontaneous circulation (ROSC).
Among 839 episodes, 465 patients received anti-hyperkalemic medication before ROSC. The rate of ROSC was higher in the no anti-hyperkalemic group than in the anti-hyperkalemic group (55.9 % vs 47.7 %, P = 0.019). The decrease in potassium level in the anti-hyperkalemic group from pre-ROSC to post-ROSC was significantly greater than that in the no anti-hyperkalemic group (coefficient 0.38, 95 % confidence interval [CI], 0.13-0.64, P = 0.003). In Cox proportional hazards regression analysis, the use of anti-hyperkalemic medication was related to a decreased ROSC rate in the overall group (adjusted hazard ratio [aHR] 0.66, 95 % CI, 0.54-0.81, P < 0.001), but there were no differences among subgroups classified according to initial potassium levels.
Anti-hyperkalemic agents were associated with substantial decreases in potassium levels in OHCA patients. However, administration of anti-hyperkalemic agents did not affect the achievement of ROSC.
我们评估了抗高钾血症药物在缓解院外心脏骤停(OHCA)患者高钾血症及改善临床结局方面的疗效。
这是一项对2010年至2020年在三级医院接受治疗的OHCA患者进行的单中心回顾性观察研究。纳入到达时处于心脏骤停状态且有心脏骤停期间血钾水平测量记录的18岁及以上成年患者。使用线性回归模型评估血钾水平变化与抗高钾血症药物使用之间的关系。进行Cox比例风险回归分析以分析抗高钾血症药物的使用与自主循环恢复(ROSC)实现之间的关系。
在839例发作中,465例患者在ROSC前接受了抗高钾血症药物治疗。无抗高钾血症组的ROSC率高于抗高钾血症组(55.9%对47.7%,P = 0.019)。抗高钾血症组从ROSC前到ROSC后的血钾水平下降显著大于无抗高钾血症组(系数0.38,95%置信区间[CI],0.13 - 0.64,P = 0.003)。在Cox比例风险回归分析中,抗高钾血症药物的使用与总体组中ROSC率降低相关(调整后风险比[aHR] 0.66,95% CI,0.54 - 0.81,P < 0.001),但根据初始血钾水平分类的亚组之间没有差异。
抗高钾血症药物与OHCA患者血钾水平的大幅下降相关。然而,抗高钾血症药物的使用并未影响ROSC的实现。